| Original language | English |
|---|---|
| Pages (from-to) | 503-505 |
| Number of pages | 3 |
| Journal | Chest |
| Volume | 157 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2020 |
ASJC Scopus Subject Areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Chest, Vol. 157, No. 3, 03.2020, p. 503-505.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Going Beyond “Bio-markers,” Think “Life-markers”
AU - Tan, Laren
AU - Chupp, Geoff
AU - Castro, Mario
AU - Kraft, Monica
N1 - Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health, American Lung Association, the Patient-Centered Outcomes Research Institute, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, and Sanofi; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona) from the National Institutes of Health, Sanofi, Regeneron, and Chiesi; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier. Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health , American Lung Association , the Patient-Centered Outcomes Research Institute , AstraZeneca , Chiesi , GlaxoSmithKline , Novartis , and Sanofi ; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona ) from the National Institutes of Health , Sanofi , Regeneron , and Chiesi ; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier.
PY - 2020/3
Y1 - 2020/3
UR - http://www.scopus.com/inward/record.url?scp=85079607748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079607748&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2019.08.2210
DO - 10.1016/j.chest.2019.08.2210
M3 - Editorial
SN - 0012-3692
VL - 157
SP - 503
EP - 505
JO - Chest
JF - Chest
IS - 3
ER -